During the recent session, Evogene Ltd (NASDAQ:EVGN)’s traded shares were 12.27 million, with the beta value of the company hitting 1.40. At the last check today, the stock’s price was $2.43, reflecting an intraday gain of 1.25% or $0.03. The 52-week high for the EVGN share is $10.40, that puts it down -327.98 from that peak though still a striking 11.93% gain since the share price plummeted to a 52-week low of $2.14. The company’s market capitalization is $13.04M, and the average intraday trading volume over the past 10 days was 55460.0 shares, and the average trade volume was 30.71K shares over the past three months.
Evogene Ltd (EVGN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. EVGN has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.01.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Evogene Ltd (NASDAQ:EVGN) trade information
Evogene Ltd (EVGN) registered a 1.25% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.25% in intraday trading to $2.43, hitting a weekly high. The stock’s 5-day price performance is 1.25%, and it has moved by -16.21% in 30 days. Based on these gigs, the overall price performance for the year is -49.28%. The short interest in Evogene Ltd (NASDAQ:EVGN) is 26791.0 shares and it means that shorts have 1.0 day(s) to cover.
The consensus price target of analysts on Wall Street is $12, which implies an increase of 79.75% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $12 respectively. As a result, EVGN is trading at a discount of -393.83% off the target high and -393.83% off the low.
Evogene Ltd (EVGN) estimates and forecasts
Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -1,162.50% this quarter and then drop -369.20% in the quarter after that. In the rating firms’ projections, revenue will increase 167.70% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 2.85M as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 7.15M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 3.77M and 578k respectively. In this case, analysts expect current quarter sales to shrink by -24.30% and then jump by 1,137.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 8.30%. While earnings are projected to return 29.90% in 2024.
EVGN Dividends
Evogene Ltd is due to release its next quarterly earnings on 2024-Nov-10. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 0.22 million shares, is of MORGAN STANLEY’s that is approximately 0.4315% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.14 million.
